BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

161 related articles for article (PubMed ID: 17332613)

  • 1. 18F-fluorodeoxythymidine PET for evaluating the response to hyperthermic isolated limb perfusion for locally advanced soft-tissue sarcomas.
    Been LB; Suurmeijer AJ; Elsinga PH; Jager PL; van Ginkel RJ; Hoekstra HJ
    J Nucl Med; 2007 Mar; 48(3):367-72. PubMed ID: 17332613
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Imaging proliferation in brain tumors with 18F-FLT PET: comparison with 18F-FDG.
    Chen W; Cloughesy T; Kamdar N; Satyamurthy N; Bergsneider M; Liau L; Mischel P; Czernin J; Phelps ME; Silverman DH
    J Nucl Med; 2005 Jun; 46(6):945-52. PubMed ID: 15937304
    [TBL] [Abstract][Full Text] [Related]  

  • 3. FDG-PET to evaluate response to hyperthermic isolated limb perfusion for locally advanced soft-tissue sarcoma.
    van Ginkel RJ; Hoekstra HJ; Pruim J; Nieweg OE; Molenaar WM; Paans AM; Willemsen AT; Vaalburg W; Koops HS
    J Nucl Med; 1996 Jun; 37(6):984-90. PubMed ID: 8683328
    [TBL] [Abstract][Full Text] [Related]  

  • 4. L-[1-11C]-tyrosine PET to evaluate response to hyperthermic isolated limb perfusion for locally advanced soft-tissue sarcoma and skin cancer.
    van Ginkel RJ; Kole AC; Nieweg OE; Molenaar WM; Pruim J; Koops HS; Vaalburg W; Hoekstra HJ
    J Nucl Med; 1999 Feb; 40(2):262-7. PubMed ID: 10025833
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Imaging bone and soft tissue tumors with the proliferation marker [18F]fluorodeoxythymidine.
    Buck AK; Herrmann K; Büschenfelde CM; Juweid ME; Bischoff M; Glatting G; Weirich G; Möller P; Wester HJ; Scheidhauer K; Dechow T; Peschel C; Schwaiger M; Reske SN
    Clin Cancer Res; 2008 May; 14(10):2970-7. PubMed ID: 18445694
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Histopathologic validation of 3'-deoxy-3'-18F-fluorothymidine PET in squamous cell carcinoma of the oral cavity.
    Troost EG; Bussink J; Slootweg PJ; Peeters WJ; Merkx MA; van der Kogel AJ; Oyen WJ; Kaanders JH
    J Nucl Med; 2010 May; 51(5):713-9. PubMed ID: 20395329
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Correlating metabolic activity on 18F-FDG PET/CT with histopathologic characteristics of osseous and soft-tissue sarcomas: a retrospective review of 136 patients.
    Rakheja R; Makis W; Skamene S; Nahal A; Brimo F; Azoulay L; Assayag J; Turcotte R; Hickeson M
    AJR Am J Roentgenol; 2012 Jun; 198(6):1409-16. PubMed ID: 22623556
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Early determination of prognosis by interim 3'-deoxy-3'-18F-fluorothymidine PET in patients with non-Hodgkin lymphoma.
    Lee H; Kim SK; Kim YI; Kim TS; Kang SH; Park WS; Yun T; Eom HS
    J Nucl Med; 2014 Feb; 55(2):216-22. PubMed ID: 24365650
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Evaluation of a new visual uptake scoring scale for 18F-fluorothymidine positron emission tomography in the diagnosis of pulmonary lesions.
    Beauregard JM; Giraudet AL; Aide N; Hofman MS; Blum R; Drummond E; Roselt P; Hicks RJ
    Nucl Med Commun; 2013 Jun; 34(6):521-6. PubMed ID: 23542911
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparison of 18F-FLT PET and 18F-FDG PET in esophageal cancer.
    van Westreenen HL; Cobben DC; Jager PL; van Dullemen HM; Wesseling J; Elsinga PH; Plukker JT
    J Nucl Med; 2005 Mar; 46(3):400-4. PubMed ID: 15750150
    [TBL] [Abstract][Full Text] [Related]  

  • 11. 18F-FLT PET does not discriminate between reactive and metastatic lymph nodes in primary head and neck cancer patients.
    Troost EG; Vogel WV; Merkx MA; Slootweg PJ; Marres HA; Peeters WJ; Bussink J; van der Kogel AJ; Oyen WJ; Kaanders JH
    J Nucl Med; 2007 May; 48(5):726-35. PubMed ID: 17475960
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Imaging proliferation in lung tumors with PET: 18F-FLT versus 18F-FDG.
    Buck AK; Halter G; Schirrmeister H; Kotzerke J; Wurziger I; Glatting G; Mattfeldt T; Neumaier B; Reske SN; Hetzel M
    J Nucl Med; 2003 Sep; 44(9):1426-31. PubMed ID: 12960187
    [TBL] [Abstract][Full Text] [Related]  

  • 13. 18F-FLT PET/CT for early response monitoring and dose escalation in oropharyngeal tumors.
    Troost EG; Bussink J; Hoffmann AL; Boerman OC; Oyen WJ; Kaanders JH
    J Nucl Med; 2010 Jun; 51(6):866-74. PubMed ID: 20484426
    [TBL] [Abstract][Full Text] [Related]  

  • 14. 18F-fluorodeoxyglucose uptake of bone and soft tissue sarcomas in pediatric patients.
    Walter F; Federman N; Apichairuk W; Nelson S; Phelps ME; Allen-Auerbach M; Walter MA; Czernin J
    Pediatr Hematol Oncol; 2011 Oct; 28(7):579-87. PubMed ID: 21936620
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [18F]FLT-PET and [18F]FDG-PET in the evaluation of radiotherapy for laryngeal cancer.
    Been LB; Hoekstra HJ; Suurmeijer AJ; Jager PL; van der Laan BF; Elsinga PH
    Oral Oncol; 2009 Dec; 45(12):e211-5. PubMed ID: 19692292
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Imaging of proliferation in hepatocellular carcinoma with the in vivo marker 18F-fluorothymidine.
    Eckel F; Herrmann K; Schmidt S; Hillerer C; Wieder HA; Krause BJ; Schuster T; Langer R; Wester HJ; Schmid RM; Schwaiger M; Buck AK
    J Nucl Med; 2009 Sep; 50(9):1441-7. PubMed ID: 19690030
    [TBL] [Abstract][Full Text] [Related]  

  • 17. 18F-FLT PET performs better than 18F-FDG PET in differentiating malignant uterine corpus tumors from benign leiomyoma.
    Yamane T; Takaoka A; Kita M; Imai Y; Senda M
    Ann Nucl Med; 2012 Jul; 26(6):478-84. PubMed ID: 22477262
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Detection of gastric cancer using 18F-FLT PET: comparison with 18F-FDG PET.
    Kameyama R; Yamamoto Y; Izuishi K; Takebayashi R; Hagiike M; Murota M; Kaji M; Haba R; Nishiyama Y
    Eur J Nucl Med Mol Imaging; 2009 Mar; 36(3):382-8. PubMed ID: 18985344
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Feasibility and efficacy of external beam radiotherapy after hyperthermic isolated limb perfusion with TNF-alpha and melphalan for limb-saving treatment in locally advanced extremity soft-tissue sarcoma.
    Olieman AF; Pras E; van Ginkel RJ; Molenaar WM; Schraffordt Koops H; Hoekstra HJ
    Int J Radiat Oncol Biol Phys; 1998 Mar; 40(4):807-14. PubMed ID: 9531364
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Can 3'-Deoxy-3'-((18)F) Fluorothymidine Out Perform 2-Deoxy-2-((18)F) Fluoro-D-Glucose Positron Emission Tomography/Computed Tomography in the Diagnosis of Cervical Lymphadenopathy in Patients With Oral/Head and Neck Cancer?
    Schaefferkoetter JD; Carlson ER; Heidel RE
    J Oral Maxillofac Surg; 2015 Jul; 73(7):1420-8. PubMed ID: 25869746
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.